Cashman Neil 4

What Happened
Neil Cashman, Chief Scientific Officer and a director of ProMIS Neurosciences (PMN), participated in a private placement on Feb. 3, 2026. He acquired 4,122 common shares at $12.13 per share (total ≈ $50,000) and, in the same transaction, received common share warrants to purchase 4,122 additional shares. The filing reports the derivative (warrant) line with no dollar amount on the Form 4; a footnote states the purchase price was $12.13 per common share and per warrant under the Securities Purchase Agreement with selected investors.

Key Details

• Transaction date: February 3, 2026; Form 4 filed February 5, 2026 (timely).
• Primary purchase: 4,122 common shares at $12.13 each — reported value ≈ $50,000.
• Derivative award: Common share warrants to purchase 4,122 shares (warrant line shown as N/A in the filing).
• Footnote: The shares and warrants were acquired under a Securities Purchase Agreement; the footnote specifies $12.13 per common share and per common share warrant.
• Warrant expiration: expires on the earlier of (i) Feb. 3, 2031 or (ii) within 60 days of public announcement or an 8‑K filing of topline data from cohorts treated with single ascending doses of PMN310.
• Reverse split: filing reflects a 1-for-25 reverse split of common shares effective Nov. 28, 2025.
• Shares owned after transaction: not stated in the provided filing.

Context
This was a private placement (not an open-market purchase), so Cashman’s acquisition reflects participation in a financing rather than a market buy. The warrants are a derivative right to buy shares later (not immediate additional shares); exercise would require a future action and payment. The 60‑day acceleration clause ties warrant life to certain topline clinical data announcements for PMN310. The filing appears timely (reported within the usual Form 4 deadline).